Core Viewpoint - Yipin Hong (300723) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Company Summary - The approved product, Methacholine Chloride Injection, is indicated for the antagonism of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - According to data from Minet, the sales scale of Methacholine Chloride in urban and county-level public hospitals in China is projected to be approximately 791 million yuan in 2024 [1]

Core Viewpoint - Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Injection from the National Medical Products Administration, indicating a significant regulatory approval for a new product in its portfolio [1] Group 1: Product Details - Methacholine Injection is indicated for the reversal of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, treatment of myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - Methacholine is classified as a competitive acetylcholinesterase inhibitor, which works by reducing the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft to compete with non-depolarizing neuromuscular blockers [1]

Core Viewpoint - Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for a new product in its portfolio [1] Group 1: Product Information - Methacholine Chloride Injection is indicated for the reversal of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, treatment of myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - Methacholine Chloride is classified as a competitive acetylcholinesterase inhibitor, which works by reducing the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft to compete with non-depolarizing neuromuscular blockers [1]

Core Viewpoint - The company has received approval for its new drug, Methylthio-2-aminobutane injection, which is indicated for various medical conditions, enhancing its product portfolio and potential market reach [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Methylthio-2-aminobutane injection [1] - The approved drug is an anticholinesterase agent, used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery [1] Group 2: Product Indications - The indications for Methylthio-2-aminobutane injection include treatment for myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1]

关于全资子公司获得甲硫酸新斯的明注射液注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州市联瑞 制药有限公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明 注射液的《药品注册证书》，现将有关事项公告如下： 一、药品注册证书主要信息 证券代码：300723 证券简称：一品红 公告编号：2025-065 一品红药业集团股份有限公司 药品通用名称：甲硫酸新斯的明注射液 英文名/拉丁名：Neostigmine Methylsulfate Injection 主要成份：甲硫酸新斯的明 剂 型：注射剂 注册分类：化学药品 3 类 规 格：4ml:2mg 药品注册标准编号：YBH25642025 药品有效期：24 个月 生产企业：广州市联瑞制药有限公司 生产企业地址：广州市南沙区万顷沙镇同发路 2 号 药品批准文号：国药准字 H20255676 药品批准文号有效期：至 2030 年 10 月 13 日 申请事项：药品注册（境内生产） 包装规格： 5 支/盒 处方药/非处方药：处方药 审批结论 ...

Core Viewpoint - The company Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration [1] Group 1 - The approved product, Methacholine Chloride Injection, is indicated for use as an anticholinesterase agent [1] - The injection is used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional bowel distension, and urinary retention [1]

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 216.94%, but recent declines in the short term indicate potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main business revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the first half of 2025, Yipinhong reported an operating income of 584 million yuan, a year-on-year decrease of 36.02%. The net profit attributable to the parent company was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, the number of Yipinhong's shareholders was 18,900, a decrease of 11.34% from the previous period. The average circulating shares per person increased by 12.79% to 22,055 shares [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included a new entrant, E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On October 15, Yipinhong's stock rose by 2.06%, reaching 54.07 yuan per share, with a trading volume of 159 million yuan and a turnover rate of 0.71%. The total market capitalization stood at 24.423 billion yuan [1]. - The stock has experienced significant fluctuations, with a recent decline of 9.02% over the last five trading days and a 21.13% drop over the past 20 days [1].

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300723 | 一品红 | 52.98 | -14.30% | 17.20万 | 9.79亿 | | 300558 | 贝达药业 | 58.34 | -10.63% | 21.05万 | 12.63亿 | | 688266 | 泽瑞制药 | 93.60 | -7.60% | 5.61万 | 5.40 乙 | | 300233 | 金城医药 | 17.28 | -6.80% | 19.79万 | 3.53亿 | | 301246 | 宏源药业 | 16.57 | -6.33% | 47.42万 | 8.29 Z | | 688506 | 百利天恒 | 338.98 | -6.18% | 1.46万 | 5.05亿 | | 300204 | 舒泰神 | 32.23 | -5.65% | 20.20万 | 6.71亿 | | 300584 | 海辰药业 | 56.94 | -5.63% | 7.36万 | 4.30亿 | | 688382 | 益方生物 ...

Group 1 - The core viewpoint of the news is that Yipinhong Pharmaceutical Group Co., Ltd. has seen a significant stock price increase of 5.35%, reaching 61.40 CNY per share, with a total market capitalization of 27.734 billion CNY [1] - Yipinhong's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals, with revenue composition being 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1] Group 2 - From the perspective of fund holdings, Yipinhong is a significant investment for Huabao Fund, with its Huabao Medical Biotechnology Mixed A Fund holding 373,000 shares, accounting for 3.59% of the fund's net value, making it the ninth largest holding [2] - The Huabao Medical Biotechnology Mixed A Fund has achieved a year-to-date return of 57.32%, ranking 622 out of 8234 in its category, and a one-year return of 41.08%, ranking 1680 out of 8083 [2] Group 3 - The fund manager of Huabao Medical Biotechnology Mixed A Fund is Zhang Jintao, who has been in the position for nearly 10 years, with the fund's total asset size at 1.202 billion CNY [3] - During Zhang's tenure, the best fund return was 62.24%, while the worst return was -14.23% [3]

Group 1 - The company Yipinhong (300723) reported that as of September 30, 2025, the total number of shareholders is 18,937 [1]